Skip to main content
. Author manuscript; available in PMC: 2022 Jul 8.
Published in final edited form as: Ann Rheum Dis. 2022 Apr 12;81(7):1006–1012. doi: 10.1136/annrheumdis-2021-221985

Figure 3. Inhibition of GC formation and reduction of NP-specific Ab production by MCC950.

Figure 3.

B6 female mice were immunized i.p. with 100 μg NP33-CGG and alum. They were treated i.p. daily with vehicle, MCC950 (20 mg/Kg). (A) Splenic GC were stained as labeled indicated by arrows. There is an absence of centroblast division in the spleen of MCC950 treated mice. (B) The integrated density (IntDen) of Ki67 staining in each GC was calculated by the ImageJ software. (C) Anti-NP IgM and IgG levels in serum samples 14 days after immunization were assayed by ELISA using NP2-BSA as coating Ag. Mean absorbance from 10,000-fold diluted samples of 5 mice per group is shown. *p < 0.05.